Usefulness of CURB-65, pneumonia severity index and MuLBSTA in predicting COVID-19 mortality

Image by <a href="https://pixabay.com/users/www_infotimisoara_ro-14737829/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5418249">Viorel Vașadi</a> from <a href="https://pixabay.com//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5418249">Pixabay</a>
Submitted: August 17, 2021
Accepted: February 14, 2022
Published: February 22, 2022
Abstract Views: 1560
PDF: 456
Supplementary: 148
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The aim of our study is to evaluate the accuracy of CURB-65 and Pneumonia Severity Index (PSI), the most widely used scores for community acquired pneumonia, and MuLBSTA, a viral pneumonia score, in predicting 28-day mortality in Coronavirus Disease 2019 (COVID-19) pneumonia.We retrospectively collected clinical data of consecutive patients with laboratory-confirmed COVID-19 pneumonia admitted at Papa Giovanni XXIII Hospital from February 23rd to March 14th, 2020. We calculated at Emergency Department (ED) presentation CURB-65, PSI and MuLBSTA and we compared their performances in discriminating between survivors and non-survivors at 28 days. Among 431 hospitalized patients, the majority presented with hypoxic respiratory failure: median (interquartile range, IQR) PaO2/FiO2 ratio at admission was 228.6 (142.0-278.1). In the first 24 hours, 111 (27%) patients were administered low-flow oxygen cannula, 50 (12%) Venturi Mask, 95 (23%) non-rebreather mask, 106 (26%) non-invasive ventilation, 12 (3%) mechanical ventilation and 41 (9%) were not administered oxygen therapy. Mortality rate at 28-day was 35% (150/431). Between survivors and non-survivors, median (IQR) scores were, respectively, 1.0 (1.0-2.0) and 2.0 (2.0-3.0) for CURB-65 (p<0.001); 90.5 (76.0-105.5) and 115.0 (100.0-129.0) for PSI (p<0.001); 7.0 (5.0-10.0) and 11.0 (9.0-13.0) for MuLBSTA (p<0.001). Areas under the receiver operating characteristic curve (AUCs) for each score were, respectively, 0.725 (0.662-0.787), 0.776 (0.693-0.859) and 0.743 (0.680-0.806) (p>0,05). PSI and MuLBSTA did not show a better performance when compared to CURB-65. Although CURB-65, PSI and MuLBSTA scores are useful tools to discriminate between survivors and non-survivors in COVID-19 pneumonia, their diagnostic accuracy in discriminating 28-day mortality in COVID-19 pneumonia is moderate, as confirmed by AUCs <0.80, and there is a potential underestimation of disease severity in the low-risk classes. For this reason, they should not be recommended in ED to decide between inpatient and outpatient management in patients affected by COVID-19 pneumonia.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845. DOI: https://doi.org/10.2307/2531595
Estella A. Usefulness of CURB-65 and pneumonia severity index for influenza A H1N1v pneumonia. Monaldi Arch Chest Dis 2012;77:118-21. DOI: https://doi.org/10.4081/monaldi.2012.144
Kim MA, Park JS, Lee CW, Choi W Il. Pneumonia severity index in viral community acquired pneumonia in adults. PLoS One 2019;14:1-12. DOI: https://doi.org/10.1371/journal.pone.0210102
Guo L, Wei D, Zhang X, et al. Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA score. Front Microbiol 2019;10:2752. DOI: https://doi.org/10.3389/fmicb.2019.02752
Bradley P, Frost F, Tharmaratnam K, Wootton DG. Utility of established prognostic scores in COVID-19 hospital admissions: Multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA. BMJ Open Respir Res 2020;7:1-9. DOI: https://doi.org/10.1136/bmjresp-2020-000729
Nguyen Y, Corre F, Honsel V, et al. Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19. J Infect 2020;81:e96-e98. DOI: https://doi.org/10.1016/j.jinf.2020.05.049
Novelli L, Raimondi F, Ghirardi A, et al. At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy. Panminerva Med 2021;63:51-61. DOI: https://doi.org/10.23736/S0031-0808.20.04063-X
Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: The CALL score. Clin Infect Dis 2020;71:1393-9. DOI: https://doi.org/10.1093/cid/ciaa414
Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: Development and validation of the 4C mortality score. BMJ 2020;370:1-13. DOI: https://doi.org/10.1136/bmj.m3339
Haimovich AD, Ravindra NG, Stoytchev S, et al. Development and validation of the quick COVID-19 severity index: A prognostic tool for early clinical decompensation. Ann Emerg Med 2020;76:442-53. DOI: https://doi.org/10.1016/j.annemergmed.2020.07.022

How to Cite

Preti, Carlo, Roberta Biza, Luca Novelli, Arianna Ghirardi, Caterina Conti, Chiara Galimberti, Lorenzo Della Bella, Irdi Memaj, Fabiano Di Marco, and Roberto Cosentini. 2022. “Usefulness of CURB-65, Pneumonia Severity Index and MuLBSTA in Predicting COVID-19 Mortality”. Monaldi Archives for Chest Disease 92 (4). https://doi.org/10.4081/monaldi.2022.2054.